Pen Needles Market - Global Outlook & Forecast 2022-2027
Description
Pen Needles Market - Global Outlook & Forecast 2022-2027
The global pen needles market is expected t grow at a CAGR of 6.09% during 2022 t 2027.
MARKET OVERVIEW
Pen needles are the needles that are attached t the durable or prefilled pens that the patients use t inject the medication. The pen needles are found mainly among insulin users, growth hormone users, and other self-injecting medication users.
The advancements in needle manufacturing technology have resulted in shorter and thinner needles. This has helped the vendors t reduce needle stick injuries. This even made vendors focus on thinner and thinner needles. These thinner needles are more user-friendly, progressively improving patient self-rating of injection comfort. BD (Becton, Dickinson) is one of the key innovative players and launched many revolutionary products in the pen needles segment.
Growth in the market is largely driven by the growing prevalence of the diabetic population and the favorable demand for self-injection devices. On the other hand, the preference for alternative modes of drug delivery, poor reimbursement in developing countries, and needle anxiety are expected t restrain the overall market growth. The growing preference for biosimilar drugs and emerging markets are areas of opportunity in the market.
All injector pens require single-use replaceable pen needles for each injection. The companies offer pen needles in various lengths t accommodate varying depths of subcutaneous tissue under the top of the skin. Pen needles are designed for single-use subcutaneous injection of medication and are not intended t be reused for more than one administration. The pen needles are generally manufactured with an outer protective plastic shell, which a person uses t attach the needle t the pen, and an inner plastic shell protecting the needle itself. The doctor or nurse's responsibility instructs how t attach and use needles t ensure proper use properly.
MARKET TRENDS & DRIVERS
The Rising Prevalence of Diabetic Population
Diabetes prevalence in all regions is predicted t rise in the coming years due t unhealthy diets and bad lifestyle choices. The countries are increasingly putting in demand for medication in recent years, majorly the low-income countries, as the patients are more convenient with injector pens. The rising incidences of needle-stick injuries due t the high usage of 8mm syringes and lack of awareness & education in low-middle income countries are als one of the main reasons for the higher adoption of insulin pen needles.
When compared with developed countries, developing countries are more prone t diabetes. In these regions, young children are als affected by diabetes due t childhood obesity, which is a significant risk factor. In the case of developed countries, only older people get affected by diabetes. In contrast, in developing countries, individuals of the adult age and elderly persons above 65 are als prone t diabetes. One in 11 adults in the age group 0-79 is affected with diabetes, especially type-II, which is attributable t lifestyle changes.
Growing Demand for Self-Injection Devices
Devices for self-injection, chiefly pens used for the subcutaneous delivery of biopharmaceuticals, constitute a growing segment of the world of drug delivery devices. With the trend toward biological drugs that cannot be administered orally and the worldwide increase in diabetes, their importance is set t grow further in the future. With the large number of new injectables expected t enter the market in the coming years, the trend t shift treatment from the clinic t the home environment t save costs and provide more patient convenience is increasing the demand for self-injection devices. Self-injection solutions can als significantly improve the quality of care from the patient's perspective. Self-administration by the patient (e.g., using an injection pen) has several advantages. For drugs requiring a subcutaneous application, self-injection pens offer an ideal opportunity t control the time factor and reduce risk.
Technological Advancements in Pen Needles
New pen needles, which are better than the conventional ones, are being introduced t the market. These next-generation pen needles will significantly add an advantage t healthcare providers, nurses, and at-home settings. This trend states that the manufacturers are focusing on improving the traditional portfolios for pen needles. The needle-stick injuries and non-adherence t the therapies are the significant phenomenon in which the manufacturers try t minimize and deliver the medication safely t the patients. There are few manufacturers whose products are top-selling in the market. T reduce risk, those companies have improved their traditional portfoli of pen needles with technology.
Growing Demand for Safety Pen Needles
Accidental blood exposures are caused by contaminated needle sticks, sharps, or splashes and expose HCPs and non-healthcare users t the risk of serious infections. Pen needles with automatic protective safety features allow patients wh are temporarily incompetent t continue self-administering drugs with assistance but without compromising healthcare provider (HCP) safety. Moreover, safety pen needles (SPNs) have been found t minimize the risk of exposure t bloodborne infections associated with needle-stick injury without any related adverse events. Safety devices are one of the most effective risk-control measures t prevent healthcare workers' exposure t injuries and infectious agents. Over 80% of NSIs can be prevented with the use of sharps with engineered sharps injury protection system.
SEGMENTATION ANALYSIS
Product Type Analysis
Based on product type, the market is segmented int standard pen needles and safety pen needles. In 2021, standard pen needles held the largest of 71.72% in the global market due t their daily usage of larger doses by diabetic patients. However, these needles are less preferred as they have a higher risk of needle-stick injury and interfere with the safe use of pen needles. Therefore, they are expected t be in low demand soon. Increasing diabetes and awareness of insulin pen use are some factors that support this segment's growth. Safety pen needles are expected t witness favorable growth during the forecast period due t technological advances in this segment and increased launches of next-generation products. These devices make it possible t minimize needle-stick injuries t patients.
Segmentation by Product Type
Based on needle length, it is segmented int short needles and long needles. The short needle segment accounted for the largest share of 78.30% in the global market in 2021. Amongst the short needle lengths, 4 mm-sized pen needles are most prescribed t all patients, including obese people suffering from the target disease. Patients are increasingly using the shortest and thinnest needles due t a greater comfort level offered by them as compared t injections. Moreover, their short layer helps reach the subcutaneous tissue of the patients easily.
Segmentation by Length
The market is segmented on therapy int insulin and non-insulin. The insulin pen needles market accounted for the largest share of 81.20% in the global market in 2021 and is als expected t showcase lucrative growth over the forecast period. This is due t the increasing awareness about the self-administration of insulin therapy amongst type 1 and types 2 diabetes patients. In non-insulin therapy, GLP-1 and growth hormone therapy is expected t exhibit significant growth soon. This is due t its capability t minimize the blood glucose level amongst patients wh have type 2 diabetes.
Segmentation by Therapy
The global pen needles market is segmented int retail and online based on distribution channels. The retail segment accounted for the largest share of 76.96% in the global pen needles market in 2021. In the retail segment, hospitals and clinics play a major role in distributing pen needles. The retailer pharmacies prefer t collaborate with hospitals and clinics t get a huge profit as the hospitals and clinics are the first points of contact. Online distribution channels are expected t grow drastically in the coming era. The COVID-19 pandemic has opened the doors for online platforms t surge the demand for pen needles in the market.
Segmentation by Distribution Channel
The Europe region is dominating the market and accounts for the share of 33.85%, followed by North America with the share of 29.65%, APAC with a share of 24.90%, Latin America with a share of 7.48%, and the Middle East & Africa region accounted for the share of 6.12% in the global market.
Segmentation by Geography
France
UK
Italy
Spain
Canada
Mexico
Argentina
Japan
India
South Korea
Australia
South Africa
Saudi Arabia
VENDOR ANALYSIS
The key companies profiled in the global pen needles market are:
Other Prominent Vendors
One of the key vendors, B.Braun Melsungen, is launching the second-generation needles, and other vendors are als coming up with safety needles in the market. These are largely adopted among the developed countries in the market. The increasing target population and adoption of advanced technologies like pen needles in Europe make them dominate the market. This is making the vendors focus the product launches across Europe. The major vendors continuously compete for the leading position in the market, with occasional spurts of competition coming from other local vendors.
KEY QUESTIONS ANSWERED:
1. How big is the global pen needle market?
2. What is the growth rate of the global pen needle market?
3. Wh are the key players in the global pen needle market?
4. What are the growth enablers in the global pen needle market?
5. Which region is expected t hold the largest share by 2027?
The global pen needles market is expected t grow at a CAGR of 6.09% during 2022 t 2027.
MARKET OVERVIEW
Pen needles are the needles that are attached t the durable or prefilled pens that the patients use t inject the medication. The pen needles are found mainly among insulin users, growth hormone users, and other self-injecting medication users.
The advancements in needle manufacturing technology have resulted in shorter and thinner needles. This has helped the vendors t reduce needle stick injuries. This even made vendors focus on thinner and thinner needles. These thinner needles are more user-friendly, progressively improving patient self-rating of injection comfort. BD (Becton, Dickinson) is one of the key innovative players and launched many revolutionary products in the pen needles segment.
Growth in the market is largely driven by the growing prevalence of the diabetic population and the favorable demand for self-injection devices. On the other hand, the preference for alternative modes of drug delivery, poor reimbursement in developing countries, and needle anxiety are expected t restrain the overall market growth. The growing preference for biosimilar drugs and emerging markets are areas of opportunity in the market.
All injector pens require single-use replaceable pen needles for each injection. The companies offer pen needles in various lengths t accommodate varying depths of subcutaneous tissue under the top of the skin. Pen needles are designed for single-use subcutaneous injection of medication and are not intended t be reused for more than one administration. The pen needles are generally manufactured with an outer protective plastic shell, which a person uses t attach the needle t the pen, and an inner plastic shell protecting the needle itself. The doctor or nurse's responsibility instructs how t attach and use needles t ensure proper use properly.
MARKET TRENDS & DRIVERS
The Rising Prevalence of Diabetic Population
Diabetes prevalence in all regions is predicted t rise in the coming years due t unhealthy diets and bad lifestyle choices. The countries are increasingly putting in demand for medication in recent years, majorly the low-income countries, as the patients are more convenient with injector pens. The rising incidences of needle-stick injuries due t the high usage of 8mm syringes and lack of awareness & education in low-middle income countries are als one of the main reasons for the higher adoption of insulin pen needles.
When compared with developed countries, developing countries are more prone t diabetes. In these regions, young children are als affected by diabetes due t childhood obesity, which is a significant risk factor. In the case of developed countries, only older people get affected by diabetes. In contrast, in developing countries, individuals of the adult age and elderly persons above 65 are als prone t diabetes. One in 11 adults in the age group 0-79 is affected with diabetes, especially type-II, which is attributable t lifestyle changes.
Growing Demand for Self-Injection Devices
Devices for self-injection, chiefly pens used for the subcutaneous delivery of biopharmaceuticals, constitute a growing segment of the world of drug delivery devices. With the trend toward biological drugs that cannot be administered orally and the worldwide increase in diabetes, their importance is set t grow further in the future. With the large number of new injectables expected t enter the market in the coming years, the trend t shift treatment from the clinic t the home environment t save costs and provide more patient convenience is increasing the demand for self-injection devices. Self-injection solutions can als significantly improve the quality of care from the patient's perspective. Self-administration by the patient (e.g., using an injection pen) has several advantages. For drugs requiring a subcutaneous application, self-injection pens offer an ideal opportunity t control the time factor and reduce risk.
Technological Advancements in Pen Needles
New pen needles, which are better than the conventional ones, are being introduced t the market. These next-generation pen needles will significantly add an advantage t healthcare providers, nurses, and at-home settings. This trend states that the manufacturers are focusing on improving the traditional portfolios for pen needles. The needle-stick injuries and non-adherence t the therapies are the significant phenomenon in which the manufacturers try t minimize and deliver the medication safely t the patients. There are few manufacturers whose products are top-selling in the market. T reduce risk, those companies have improved their traditional portfoli of pen needles with technology.
Growing Demand for Safety Pen Needles
Accidental blood exposures are caused by contaminated needle sticks, sharps, or splashes and expose HCPs and non-healthcare users t the risk of serious infections. Pen needles with automatic protective safety features allow patients wh are temporarily incompetent t continue self-administering drugs with assistance but without compromising healthcare provider (HCP) safety. Moreover, safety pen needles (SPNs) have been found t minimize the risk of exposure t bloodborne infections associated with needle-stick injury without any related adverse events. Safety devices are one of the most effective risk-control measures t prevent healthcare workers' exposure t injuries and infectious agents. Over 80% of NSIs can be prevented with the use of sharps with engineered sharps injury protection system.
SEGMENTATION ANALYSIS
Product Type Analysis
Based on product type, the market is segmented int standard pen needles and safety pen needles. In 2021, standard pen needles held the largest of 71.72% in the global market due t their daily usage of larger doses by diabetic patients. However, these needles are less preferred as they have a higher risk of needle-stick injury and interfere with the safe use of pen needles. Therefore, they are expected t be in low demand soon. Increasing diabetes and awareness of insulin pen use are some factors that support this segment's growth. Safety pen needles are expected t witness favorable growth during the forecast period due t technological advances in this segment and increased launches of next-generation products. These devices make it possible t minimize needle-stick injuries t patients.
Segmentation by Product Type
- Standard Pen Needles
- Safety Pen Needles
Based on needle length, it is segmented int short needles and long needles. The short needle segment accounted for the largest share of 78.30% in the global market in 2021. Amongst the short needle lengths, 4 mm-sized pen needles are most prescribed t all patients, including obese people suffering from the target disease. Patients are increasingly using the shortest and thinnest needles due t a greater comfort level offered by them as compared t injections. Moreover, their short layer helps reach the subcutaneous tissue of the patients easily.
Segmentation by Length
- Short Length
- Long Length
The market is segmented on therapy int insulin and non-insulin. The insulin pen needles market accounted for the largest share of 81.20% in the global market in 2021 and is als expected t showcase lucrative growth over the forecast period. This is due t the increasing awareness about the self-administration of insulin therapy amongst type 1 and types 2 diabetes patients. In non-insulin therapy, GLP-1 and growth hormone therapy is expected t exhibit significant growth soon. This is due t its capability t minimize the blood glucose level amongst patients wh have type 2 diabetes.
Segmentation by Therapy
- Insulin
- Non-Insulin
The global pen needles market is segmented int retail and online based on distribution channels. The retail segment accounted for the largest share of 76.96% in the global pen needles market in 2021. In the retail segment, hospitals and clinics play a major role in distributing pen needles. The retailer pharmacies prefer t collaborate with hospitals and clinics t get a huge profit as the hospitals and clinics are the first points of contact. Online distribution channels are expected t grow drastically in the coming era. The COVID-19 pandemic has opened the doors for online platforms t surge the demand for pen needles in the market.
Segmentation by Distribution Channel
- Retail
- Online
The Europe region is dominating the market and accounts for the share of 33.85%, followed by North America with the share of 29.65%, APAC with a share of 24.90%, Latin America with a share of 7.48%, and the Middle East & Africa region accounted for the share of 6.12% in the global market.
Segmentation by Geography
- Europe
France
UK
Italy
Spain
- North America
Canada
- Latin America
Mexico
Argentina
- APAC
Japan
India
South Korea
Australia
- Middle East & Africa
South Africa
Saudi Arabia
VENDOR ANALYSIS
The key companies profiled in the global pen needles market are:
- BD
- Braun Melsungen
- Nov Nordisk
- Owen Mumford
- Ypsomed
Other Prominent Vendors
- AdvaCare Pharma
- Allison Medical
- ARKRAY
- GlucoRx
- Hindustan Syringes & Medical Devices
- HTL-STREFA
- IGAKU NEEDLES
- Iyon Medical
- Links Medical Products
- MedExel
- Medivena
- Montméd
- Narang Medical
- Nipr Europe Group Companies
- Promisemed Medical Devices
- SHANGHAI BERPU MEDICAL
- Simple Diagnostics
- Terum Europe
- Trividia Health
- UltiMed
- Van Heek Medical
- VOGT MEDICAL
One of the key vendors, B.Braun Melsungen, is launching the second-generation needles, and other vendors are als coming up with safety needles in the market. These are largely adopted among the developed countries in the market. The increasing target population and adoption of advanced technologies like pen needles in Europe make them dominate the market. This is making the vendors focus the product launches across Europe. The major vendors continuously compete for the leading position in the market, with occasional spurts of competition coming from other local vendors.
KEY QUESTIONS ANSWERED:
1. How big is the global pen needle market?
2. What is the growth rate of the global pen needle market?
3. Wh are the key players in the global pen needle market?
4. What are the growth enablers in the global pen needle market?
5. Which region is expected t hold the largest share by 2027?
Table of Contents
325 Pages
- 1 RESEARCH METHODOLOGY
- 2 RESEARCH OBJECTIVES
- 3 RESEARCH PROCESS
- 4 SCOPE & COVERAGE
- 4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
- 4.2 BASE YEAR
- 4.3 SCOPE OF THE STUDY
- 4.3.1 MARKET SEGMENTATION BY PRODUCT TYPE
- 4.3.2 MARKET SEGMENTATION BY LENGTH
- 4.3.3 MARKET SEGMENTATION BY THERAPY
- 4.3.4 MARKET SEGMENTATION BY DISTRIBUTION CHANNEL
- 4.3.5 MARKET SEGMENTATION BY GEOGRAPHY
- 5 REPORT ASSUMPTIONS & CAVEATS
- 5.1 KEY CAVEATS
- 5.2 CURRENCY CONVERSION
- 5.3 MARKET DERIVATION
- 6 MARKET AT A GLANCE
- 7 PREMIUM INSIGHTS
- 7.1 OVERVIEW
- 7.1.1 RISING PREVALENCE OF DIABETES
- 7.1.2 GROWING DEMAND FOR SELF-INJECTION DEVICES
- 7.1.3 TECHNOLOGICAL ADVANCES IN PEN NEEDLES
- 7.1.4 GROWING DEMAND FOR SAFETY PEN NEEDLES
- 7.1.5 PRODUCT TYPE ANALYSIS
- 7.1.6 NEEDLE LENGTH ANALYSIS
- 7.1.7 THERAPY ANALYSIS
- 7.1.8 DISTRIBUTION CHANNEL
- 7.1.9 GEOGRAPHY ANALYSIS
- 8 INTRODUCTION
- 8.1 OVERVIEW
- 9 MARKET OPPORTUNITIES & TRENDS
- 9.1 SURGE IN DEMAND FOR SELF-INJECTABLE DEVICES
- 9.2 TECHNOLOGICAL ADVANCES IN PEN NEEDLES
- 9.3 GROWING PREFERENCE FOR BIOSIMILAR DRUGS
- 10 MARKET GROWTH ENABLERS
- 10.1 EXPANDING PATIENT POPULATION FOR CHRONIC DISEASES
- 10.2 GROWING DEMAND FOR SAFETY NEEDLES
- 10.3 EMERGENCE OF E-COMMERCE AS PREFERRED DISTRIBUTION CHANNEL
- 11 MARKET RESTRAINTS
- 11.1 REUSE OF PEN NEEDLES
- 11.2 NEEDLE ANXIETY & SAFETY ISSUES ASSOCIATED WITH PEN NEEDLES
- 11.3 HIGH GLOBAL PREVALENCE OF UNDIAGNOSED DIABETES
- 12 MARKET LANDSCAPE
- 12.1 MARKET OVERVIEW
- 12.2 MARKET SIZE & FORECAST
- 12.2.1 GEOGRAPHY ANALYSIS
- 12.2.2 PRODUCT TYPE ANALYSIS
- 12.2.3 LENGTH ANALYSIS
- 12.2.4 THERAPY ANALYSIS
- 12.2.5 DISTRIBUTION CHANNEL ANALYSIS
- 12.3 FIVE FORCES ANALYSIS
- 12.3.1 THREAT OF NEW ENTRANTS
- 12.3.2 BARGAINING POWER OF SUPPLIERS
- 12.3.3 BARGAINING POWER OF BUYERS
- 12.3.4 THREAT OF SUBSTITUTES
- 12.3.5 COMPETITIVE RIVALRY
- 13 PRODUCT TYPE
- 13.1 MARKET SNAPSHOT & GROWTH ENGINE
- 13.2 MARKET OVERVIEW
- 13.3 STANDARD PEN NEEDLES
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.3.3 STANDARD PEN NEEDLES SEGMENTATION BY GEOGRAPHY
- 13.4 SAFETY PEN NEEDLES
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.4.3 SAFETY PEN NEEDLES SEGMENTATION BY GEOGRAPHY
- 14 LENGTH
- 14.1 MARKET SNAPSHOT & GROWTH ENGINE
- 14.2 MARKET OVERVIEW
- 14.3 SHORT NEEDLES
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.3.3 SHORT NEEDLES SEGMENTATION BY GEOGRAPHY
- 14.4 LONG NEEDLES
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.4.3 LONG NEEDLES SEGMENTATION BY GEOGRAPHY
- 15 THERAPY
- 15.1 MARKET SNAPSHOT & GROWTH ENGINE
- 15.2 MARKET OVERVIEW
- 15.3 INSULIN
- 15.3.1 MARKET OVERVIEW
- 15.3.2 MARKET SIZE & FORECAST
- 15.3.3 INSULIN SEGMENTATION BY GEOGRAPHY
- 15.4 NON-INSULIN
- 15.4.1 MARKET OVERVIEW
- 15.4.2 MARKET SIZE & FORECAST
- 15.4.3 NON-INSULIN SEGMENTATION BY GEOGRAPHY
- 16 DISTRIBUTION CHANNEL
- 16.1 MARKET SNAPSHOT & GROWTH ENGINE
- 16.2 MARKET OVERVIEW
- 16.3 RETAIL
- 16.3.1 MARKET OVERVIEW
- 16.3.2 MARKET SIZE & FORECAST
- 16.3.3 RETAIL SEGMENTATION BY GEOGRAPHY
- 16.4 ONLINE
- 16.4.1 MARKET OVERVIEW
- 16.4.2 MARKET SIZE & FORECAST
- 16.4.3 ONLINE SEGMENTATION BY GEOGRAPHY
- 17 GEOGRAPHY
- 17.1 GEOGRAPHIC OVERVIEW
- 17.2 MARKET SNAPSHOT & GROWTH ENGINE
- 18 EUROPE
- 18.1 MARKET OVERVIEW
- 18.2 MARKET SIZE & FORECAST
- 18.2.1 EUROPE: PRODUCT TYPE SEGMENTATION
- 18.2.2 EUROPE: LENGTH SEGMENTATION
- 18.2.3 EUROPE: THERAPY SEGMENTATION
- 18.2.4 EUROPE: DISTRIBUTION CHANNEL SEGMENTATION
- 18.3 KEY COUNTRIES
- 18.3.1 GERMANY: MARKET SIZE & FORECAST
- 18.3.2 FRANCE: MARKET SIZE & FORECAST
- 18.3.3 UK: MARKET SIZE & FORECAST
- 18.3.4 ITALY: MARKET SIZE & FORECAST
- 18.3.5 SPAIN: MARKET SIZE & FORECAST
- 19 NORTH AMERICA
- 19.1 MARKET OVERVIEW
- 19.2 MARKET SIZE & FORECAST
- 19.2.1 NORTH AMERICA: PRODUCT TYPE SEGMENTATION
- 19.2.2 NORTH AMERICA: LENGTH SEGMENTATION
- 19.2.3 NORTH AMERICA: THERAPY SEGMENTATION
- 19.2.4 NORTH AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
- 19.3 KEY COUNTRIES
- 19.3.1 US: MARKET SIZE & FORECAST
- 19.3.2 CANADA: MARKET SIZE & FORECAST
- 20 APAC
- 20.1 MARKET OVERVIEW
- 20.2 MARKET SIZE & FORECAST
- 20.2.1 APAC: PRODUCT TYPE SEGMENTATION
- 20.2.2 APAC: LENGTH SEGMENTATION
- 20.2.3 APAC: THERAPY SEGMENTATION
- 20.2.4 APAC: DISTRIBUTION CHANNEL SEGMENTATION
- 20.3 KEY COUNTRIES
- 20.3.1 CHINA: MARKET SIZE & FORECAST
- 20.3.2 JAPAN: MARKET SIZE & FORECAST
- 20.3.3 INDIA: MARKET SIZE & FORECAST
- 20.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
- 20.3.5 AUSTRALIA: MARKET SIZE & FORECAST
- 21 LATIN AMERICA
- 21.1 MARKET OVERVIEW
- 21.2 MARKET SIZE & FORECAST
- 21.2.1 LATIN AMERICA: PRODUCT TYPE SEGMENTATION
- 21.2.2 LATIN AMERICA: LENGTH SEGMENTATION
- 21.2.3 LATIN AMERICA: THERAPY SEGMENTATION
- 21.2.4 LATIN AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
- 21.3 KEY COUNTRIES
- 21.3.1 BRAZIL: MARKET SIZE & FORECAST
- 21.3.2 MEXICO: MARKET SIZE & FORECAST
- 21.3.3 ARGENTINA: MARKET SIZE & FORECAST
- 22 MIDDLE EAST & AFRICA
- 22.1 MARKET OVERVIEW
- 22.2 MARKET SIZE & FORECAST
- 22.2.1 MIDDLE EAST & AFRICA: PRODUCT TYPE SEGMENTATION
- 22.2.2 MIDDLE EAST & AFRICA: LENGTH SEGMENTATION
- 22.2.3 MIDDLE EAST & AFRICA: THERAPY SEGMENTATION
- 22.2.4 MIDDLE EAST & AFRICA: DISTRIBUTION CHANNEL SEGMENTATION
- 22.3 KEY COUNTRIES
- 22.3.1 TURKEY: MARKET SIZE & FORECAST
- 22.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST
- 22.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST
- 23 COMPETITIVE LANDSCAPE
- 23.1 COMPETITION OVERVIEW
- 23.2 MARKET SHARE ANALYSIS
- 23.2.1 BD
- 23.2.2 B. BRAUN MELSUNGEN
- 23.2.3 NOVO NORDISK
- 23.2.4 OWEN MUMFORD
- 23.2.5 YPSOMED
- 24 KEY COMPANY PROFILES
- 24.1 BD
- 24.1.1 BUSINESS OVERVIEW
- 24.1.2 PRODUCT OFFERINGS
- 24.1.3 KEY STRATEGIES
- 24.1.4 KEY STRENGTHS
- 24.1.5 KEY OPPORTUNITIES
- 24.2 B. BRAUN MELSUNGEN
- 24.2.1 BUSINESS OVERVIEW
- 24.2.2 PRODUCT OFFERINGS
- 24.2.3 KEY STRATEGIES
- 24.2.4 KEY STRENGTHS
- 24.2.5 KEY OPPORTUNITIES
- 24.3 NOVO NORDISK
- 24.3.1 BUSINESS OVERVIEW
- 24.3.2 PRODUCT OFFERINGS
- 24.3.3 KEY STRATEGIES
- 24.3.4 KEY STRENGTHS
- 24.3.5 KEY OPPORTUNITIES
- 24.4 OWEN MUMFORD
- 24.4.1 BUSINESS OVERVIEW
- 24.4.2 PRODUCT OFFERINGS
- 24.4.3 KEY STRATEGIES
- 24.4.4 KEY STRENGTHS
- 24.4.5 KEY OPPORTUNITIES
- 24.5 YPSOMED
- 24.5.1 BUSINESS OVERVIEW
- 24.5.2 PRODUCT OFFERINGS
- 24.5.3 KEY STRATEGIES
- 24.5.4 KEY STRENGTHS
- 24.5.5 KEY OPPORTUNITIES
- 25 OTHER PROMINENT VENDORS
- 25.1 ADVACARE PHARMA
- 25.1.1 BUSINESS OVERVIEW
- 25.1.2 PRODUCT OFFERINGS
- 25.2 ALLISON MEDICAL
- 25.2.1 BUSINESS OVERVIEW
- 25.2.2 PRODUCT OFFERINGS
- 25.3 ARKRAY
- 25.3.1 BUSINESS OVERVIEW
- 25.3.2 PRODUCT OFFERINGS
- 25.4 GLUCORX
- 25.4.1 BUSINESS OVERVIEW
- 25.4.2 PRODUCT OFFERINGS
- 25.5 HINDUSTAN SYRINGES & MEDICAL DEVICES
- 25.5.1 BUSINESS OVERVIEW
- 25.5.2 PRODUCT OFFERINGS
- 25.6 HTL-STREFA
- 25.6.1 BUSINESS OVERVIEW
- 25.6.2 PRODUCT OFFERINGS
- 25.7 IGAKU NEEDLES
- 25.7.1 BUSINESS OVERVIEW
- 25.7.2 PRODUCT OFFERINGS
- 25.8 IYON MEDICAL
- 25.8.1 BUSINESS OVERVIEW
- 25.8.2 PRODUCT OFFERINGS
- 25.9 LINKS MEDICAL PRODUCTS
- 25.9.1 BUSINESS OVERVIEW
- 25.9.2 PRODUCT OFFERINGS
- 25.10 MEDEXEL
- 25.10.1 BUSINESS OVERVIEW
- 25.10.2 PRODUCT OFFERINGS
- 25.11 MEDIVENA
- 25.11.1 BUSINESS OVERVIEW
- 25.11.2 PRODUCT OFFERINGS
- 25.12 MONTMÉD
- 25.12.1 BUSINESS OVERVIEW
- 25.12.2 PRODUCT OFFERINGS
- 25.13 NARANG MEDICAL
- 25.13.1 BUSINESS OVERVIEW
- 25.13.2 PRODUCT OFFERINGS
- 25.14 NIPRO EUROPE GROUP COMPANIES
- 25.14.1 BUSINESS OVERVIEW
- 25.14.2 PRODUCT OFFERINGS
- 25.15 PROMISEMED MEDICAL DEVICES
- 25.15.1 BUSINESS OVERVIEW
- 25.15.2 PRODUCT OFFERINGS
- 25.16 SHANGHAI BERPU MEDICAL
- 25.16.1 BUSINESS OVERVIEW
- 25.16.2 PRODUCT OFFERINGS
- 25.17 SIMPLE DIAGNOSTICS
- 25.17.1 BUSINESS OVERVIEW
- 25.17.2 PRODUCT OFFERINGS
- 25.18 TERUMO EUROPE
- 25.18.1 BUSINESS OVERVIEW
- 25.18.2 PRODUCT OFFERINGS
- 25.19 TRIVIDIA HEALTH
- 25.19.1 BUSINESS OVERVIEW
- 25.19.2 PRODUCT OFFERINGS
- 25.20 ULTIMED
- 25.20.1 BUSINESS OVERVIEW
- 25.20.2 PRODUCT OFFERINGS
- 25.21 VAN HEEK MEDICAL
- 25.21.1 BUSINESS OVERVIEW
- 25.21.2 PRODUCT OFFERINGS
- 25.22 VOGT MEDICAL
- 25.22.1 BUSINESS OVERVIEW
- 25.22.2 PRODUCT OFFERINGS
- 26 QUANTITATIVE SUMMARY
- 26.1 MARKET BY PRODUCT TYPE
- 26.1.1 EUROPE: PRODUCT TYPE SEGMENTATION
- 26.1.2 NORTH AMERICA: PRODUCT TYPE SEGMENTATION
- 26.1.3 APAC: PRODUCT TYPE SEGMENTATION
- 26.1.4 LATIN AMERICA: PRODUCT TYPE SEGMENTATION
- 26.1.5 MIDDLE EAST & AFRICA: PRODUCT TYPE SEGMENTATION
- 26.2 MARKET BY LENGTH
- 26.2.1 EUROPE: LENGTH SEGMENTATION
- 26.2.2 NORTH AMERICA: LENGTH SEGMENTATION
- 26.2.3 APAC: LENGTH SEGMENTATION
- 26.2.4 LATIN AMERICA: LENGTH SEGMENTATION
- 26.2.5 MIDDLE EAST & AFRICA: LENGTH SEGMENTATION
- 26.3 MARKET BY THERAPY
- 26.3.1 EUROPE: THERAPY SEGMENTATION
- 26.3.2 NORTH AMERICA: THERAPY SEGMENTATION
- 26.3.3 APAC: THERAPY SEGMENTATION
- 26.3.4 LATIN AMERICA: THERAPY SEGMENTATION
- 26.3.5 MIDDLE EAST & AFRICA: THERAPY SEGMENTATION
- 26.4 MARKET BY DISTRIBUTION CHANNEL
- 26.4.1 EUROPE: DISTRIBUTION CHANNEL SEGMENTATION
- 26.4.2 NORTH AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
- 26.4.3 APAC: DISTRIBUTION CHANNEL SEGMENTATION
- 26.4.4 LATIN AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
- 26.4.5 MIDDLE EAST & AFRICA: DISTRIBUTION CHANNEL SEGMENTATION
- 26.5 MARKET BY GEOGRAPHY
- 26.5.1 STANDARD PEN NEEDLES SEGMENTATION BY GEOGRAPHY
- 26.5.2 SAFETY PEN NEEDLES SEGMENTATION BY GEOGRAPHY
- 26.5.3 SHORT NEEDLES SEGMENTATION BY GEOGRAPHY
- 26.5.4 LONG NEEDLES SEGMENTATION BY GEOGRAPHY
- 26.5.5 INSULIN SEGMENTATION BY GEOGRAPHY
- 26.5.6 NON-INSULIN SEGMENTATION BY GEOGRAPHY
- 26.5.7 RETAIL SEGMENTATION BY GEOGRAPHY
- 26.5.8 ONLINE SEGMENTATION BY GEOGRAPHY
- 27 REPORT SUMMARY
- 27.1 KEY TAKEAWAYS
- 27.2 STRATEGIC RECOMMENDATIONS
- 28 APPENDIX
- 28.1 ABBREVIATIONS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
